Patients managing both obesity and type 2 diabetes deserve multiple options that fit their needs. Katie Giblin, our Associate Vice President of Medical Development, shares what's ahead at the European Association for the Study of Diabetes conference in Milan, Italy — including new research we plan to share on how our investigational triple agonist performed in trials, and what it could mean as a future potential treatment option for people living with both conditions. #EASD2026